SCHEMBL15848552

SCHEMBL15848552

Fc1ccc(-c2cnc(C3CCCN3)[nH]2)cc1

nearest known ligand 0.50

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
SSTR3 P32745 13/20 0.50
KCNH2 Q12809 13/20 0.50
SCN10A Q9Y5Y9 1/20 0.44
SSTR5 P35346 1/20 0.43
MAPK13 O15264 1/20 0.42
MAPK12 P53778 1/20 0.42
MAPK11 Q15759 1/20 0.42
MAPK14 Q16539 1/20 0.42
HPGDS O60760 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15848551 1.00 SSTR3 (0.50) SSTR3KCNH2SCN10ASSTR5MAPK13
SCHEMBL9280936 0.93 MAPK13 (0.47) SSTR3KCNH2SCN10AMAPK13MAPK12
SCHEMBL9284198 0.93 MAPK13 (0.47) SSTR3KCNH2SCN10AMAPK13MAPK12
SCHEMBL12160056 0.91 MAPK13 (0.46) SSTR3KCNH2SCN10AMAPK13MAPK12
SCHEMBL12160014 0.91 MAPK13 (0.46) SSTR3KCNH2SCN10AMAPK13MAPK12
SCHEMBL689813 0.91 MAPK13 (0.46) SSTR3KCNH2SCN10AMAPK13MAPK12
SCHEMBL18475635 0.91 MAPK13 (0.46) SSTR3KCNH2SCN10AMAPK13MAPK12
SCHEMBL12160094 0.91 MAPK13 (0.46) SSTR3KCNH2SCN10AMAPK13MAPK12
SCHEMBL2775603 0.91 MAPK13 (0.46) SSTR3KCNH2SCN10AMAPK13MAPK12
Hydrochloric Acid SCHEMBL19689541 0.90 MAPK13 (0.45) SSTR3KCNH2SCN10AMAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118852145-A GSPT1 degradation agent and application thereof 南京圣和药业股份有限公司 2024-10-29 CN disclosed
US-9868758-B2 Betulinic proline imidazole derivatives as HIV inhibitors HETERO LABS LIMITED (IN) 2018-01-16 US disclosed
US-20170129916-A1 NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS HETERO RESEARCH FOUNDATION (IN) 2017-05-11 US disclosed
US-20170129917-A1 NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS HETERO LABS LIMITED (IN) 2017-05-11 US disclosed
US-20170129916-A1 NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS HETERO RESEARCH FOUNDATION (IN) 2017-05-11 US disclosed
US-9637516-B2 Betulinic acid proline derivatives as HIV inhibitors HETERO RESEARCH FOUNDATION (IN) 2017-05-02 US disclosed
US-20150337004-A1 NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS HETERO LABS LIMITED (IN) 2015-11-26 US disclosed
WO-2014105926-A1 NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS HETERO RESEARCH FOUNDATION (IN) 2014-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170129916-A1 NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS BET1, PRR12, PREP SSTR3 4530/4885KCNH2 4692/4885SCN10A 4631/4885
US-20170129917-A1 NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS BET1, PRR12, IMPA1 SSTR3 4586/4885KCNH2 4678/4885SCN10A 4617/4885
US-20150337004-A1 NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS BET1, PRR12, PELP1 SSTR3 4779/4885KCNH2 4854/4885SCN10A 4509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.